{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '-', '207626', 'Medical history including COPD history (comprised of COPD type [emphysema', 'and/or chronic bronchitis]), smoking history, COPD exacerbations history,', 'smoking status and previous and/or current medical conditions.', 'Demography', 'Concomitant Medications', 'COPD exacerbation assessment (documented history of exacerbation(s)', 'Cardiovascular medical history/risk factors', 'Inclusion/Exclusion criteria', 'Physical examination (including oropharyngeal examination)', 'Pulse rate, blood pressure measurements', '12-lead ECG', 'Pre-and post-albuterol/salbutamol spirometry (reversibility)', 'SAE assessment (if related to study participation)', 'Chest X-Ray or (historical radiograph obtained within 3 months prior to', 'screening)', 'Laboratory assessments (chemistry and hematology, hepatitis and pregnancy', 'testing)', 'CAT', 'Administer and dispense run-in study treatment', 'In addition the following procedures must be completed at Screening (Visit 1):', 'Smoking cessation counseling', 'Register visit in IWRS', 'Dispense albuterol/salbutamol', '9.1.', 'Efficacy Assessments', 'The timings of all efficacy assessments are specified in the SoA (Section 2).', '9.1.1.', 'Spirometry', 'Spirometry measurements will be obtained using spirometry equipment that meets or', 'exceeds the minimal performance recommendations of the American Thoracic Society', '(ATS) [Miller, 2005]. All sites will use standardised spirometry equipment provided by', 'an external vendor. All participants will have spirometry performed at screening and', 'each scheduled clinic visit during the treatment period. For FEV1 and FVC', 'determinations, at least 3 acceptable spirometry efforts (with no more than 8) should be', 'obtained. Acceptable spirometry efforts should have a satisfactory start of test and end', 'of', 'test (e.g. a plateau in the volume-time curve) and be free from artifacts due to cough,', '61']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'early termination, poor effort, obstructed mouthpiece, equipment malfunction, or other', 'reasons [Miller, 2005].', 'The largest FEV1 and FVC from the 3 acceptable efforts should be recorded, even if they', 'do not come from the same effort.', 'Spirometry must be performed as follows:', 'Started approximately between 6:00AM and 11:00AM.', 'If applicable, after completing the health outcomes assessments (CAT should be', 'administered first followed by SGRQ-C)', 'After withholding albuterol/salbutamol for >4 hours.', 'At Screening (Visit 1), before the morning dose of their usual COPD medication.', 'At Randomisation (Visit 2) and all treatment visits, before the morning dose of study', 'treatment.', 'Participants should refrain from smoking for 1 hour prior to each pulmonary function', 'test.', 'Participants should abstain from drinking beverages with high levels of caffeine such', 'as tea and coffee for 2 hours prior to each pulmonary function test.', 'A full description of the timing and conduct of spirometry procedures is provided in the', 'SRM.', '9.1.1.1.', 'Reversibility', 'At Visit 1, both pre- and post-albuterol/salbutamol spirometry will be obtained. Post-', 'albuterol/salbutamol FEV1 and FEV1/FVC findings will be used to determine participant', 'eligibility.', 'Reversibility testing will be completed as follows: Following pre-albuterol/salbutamol', 'spirometry (three acceptable spirometry efforts), the participant will self-administer 4', 'puffs of albuterol/salbutamol MDI using a spacer/valved-holding chamber. Three', 'acceptable spirometry efforts will be obtained approximately 10 to 30 minutes after', 'albuterol/salbutamo administration.', '9.1.2.', 'SGRQ-C', \"The St George's Respiratory Questionnaire-Chronic Obstructive Pulmonary Disease\", 'specific (SGRQ-C) will be completed by participants at Randomisation (Visit 2), Day 28', '(Visit 3), and Day 84 (Visit 4). When the SGRQ-C and the COPD Assessment Test', '(CAT) are collected at the same visit, the CAT should be collected prior to the SGRQ-C.', 'The SGRQ-C [Meguro, 2007] is a disease-specific questionnaire designed to measure the', \"impact of respiratory disease and its treatment on a COPD participant's HRQoL. As well\", 'as producing an overall summary score, scores for the individual domains of symptoms,', 'activity and impacts are also produced. It has been used in studies of COPD participants', 'and has been translated and validated for use in most major languages. The SGRQ-C is', '62']\n\n###\n\n", "completion": "END"}